Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne ...

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

Sarepta stock jumped after the drugmaker resumed shipments of the medicine Elevidys, previously paused by request by the FDA, ...

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

What's next for the stock market? Dow and Nasdaq futures rise as investors await Big Tech earnings and interest rate decision ...

Investor attention is shifting from geopolitics to corporate fundamentals as earnings begin to eclipse tariffs as the primary market catalyst, according to Barclays (LON:BARC).

September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning, extending yesterday’s gains, while investors ...

FDA recommends lifting the hold on Sarepta's gene therapy Elevidys for ambulatory patients after investigation; ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...